Details

Autor(en) / Beteiligte

• Hirano, Mitsuhito
• Kimura, Koichi
• Ishigaki, Tomohiro
• Nojima, Masanori
• Daimon, Masao
• Morita, Hiroyuki
• Takenaka, Katsu
• Xu, Boqing
• Sawada, Naoko
• Hirokawa, Megumi
• Komuro, Issei
• Morisaki, Takayuki
• Yotsuyanagi, Hiroshi
• Kawamata, Toyotaka
• Yokoyama, Kazuaki
• Konuma, Takaaki
• Kato, Seiko
• Yasui, Hiroshi
• Nagamura-Inoue, Tokiko
• Uchimaru, Kaoru
• Takahashi, Satoshi
• Imai, Yoichi
• Tojo, Arinobu

Titel

High Prevalence of Left Ventricular Non-Compaction and Its Effect on Chemotherapy-Related Cardiac Dysfunction in Patients With Hematological Diseases

Ist Teil von

• Circulation Journal, 2020/10/23, Vol.84(11), pp.1957-1964

Ort / Verlag

Japan: The Japanese Circulation Society

Erscheinungsjahr

2020

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Background:Recent progress in chemotherapy has prolonged the survival of patients with hematological diseases, but has also increased the number of patients with chemotherapy-related cardiac dysfunction (CTRCD). However, the causes of individual variations and risk factors for CTRCD have yet to be fully elucidated.Methods and Results:Consecutive echocardiograms of 371 patients were retrospectively evaluated for the presence of left ventricular (LV) non-compaction (LVNC). Individual LV ejection fraction (LVEF) outcome estimates were made using bivariate linear regression with log-transformed duration Akaike information criterion (AIC) model fitting. The prevalence of LVNC was 6-fold higher in patients with hematological diseases than in those with non-hematological diseases (12% vs. 2%; risk ratio 6.1; 95% confidence interval [CI] 2.0, 18.2). Among patients with hematological diseases, the ratio of myeloid diseases was significantly higher in the group with LVNC (P=0.031). Deterioration of LVEF was more severe in patients with than without LVNC (–14.4 percentage points/year [95% CI –21.0, –7.9] vs. –4.6 percentage points/year [95% CI –6.8, –2.4], respectively), even after multivariate adjustment for baseline LVEF, background disease distributions, cumulative anthracycline dose, and other baseline factors.Conclusions:LVNC is relatively prevalent in patients with hematological diseases (particularly myeloid diseases) and can be one of the major risk factors for CTRCD. Detailed cardiac evaluations including LVNC are recommended for patients undergoing chemotherapy.